Should You Buy vTv Therapeutics Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, vTv Therapeutics Inc. (VTVT) occupies a solid middle-ground position with a Quality of Company score of 6.5/10. At the current market price of $31.67, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.
The short answer: 10 of 12 CirclFi valuation models project upside for vTv Therapeutics Inc. (VTVT) at $31.67 — the model consensus leans bullish, with a Quality Score of 6.5/10 and Value-Trap risk of 47/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
Investment Thesis
The Bull Case
Target: $78.73 (+148.6% upside)
- According to the CirclFi Deep Alpha Valuation Engine, the stock shows multi-model upside with an average implied return of +36.0% across 9 bullish models from the current price of $31.67.
- According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model targets a fair value of $78.73 (+148.6%), anchoring the bull case with a methodology that provides a differentiated analytical lens.
- Industry tailwind: therapeutic area leadership could provide meaningful support for vTv Therapeutics Inc.'s revenue and margin trajectory in the Pharmaceutical Preparations space.
The Bear Case
Target: $29.50 (-6.9%)
- According to the CirclFi Value Trap algorithm, the stock shows moderate caution signals, meaning investors should verify that apparent undervaluation isn't masking declining business quality.
- According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +155.5% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.
- Industry headwind: drug pricing legislation represents a meaningful risk for vTv Therapeutics Inc. and its Pharmaceutical Preparations peers.
The Bottom Line
The convergence of 6.5/10 quality, multi-model undervaluation (9/12 bullish, +36.0% avg. upside), and a composite fair value of $43.08 vs. $31.67 current price makes vTv Therapeutics Inc. one of the more compelling opportunities in our coverage. As always, our models provide a quantitative starting point — not a substitute for individual due diligence.
These are quantitative model outputs, not investment recommendations. vTv Therapeutics Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
Frequently Asked Questions
Should I buy VTVT stock right now?
Based on CirclFi's multi-model analysis, 10 of 12 models see upside for VTVT at $31.67. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 6.5/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in vTv Therapeutics Inc.?
Key risks include: an elevated Value Trap score of 47/100, suggesting apparent undervaluation may mask deteriorating fundamentals; wide model disagreement (167% spread), signaling high uncertainty; general market and sector-specific risks affecting Pharmaceutical Preparations companies. Always diversify and consult a financial advisor.
How does VTVT compare to its competitors?
Among Pharmaceutical Preparations peers, VTVT holds a Quality Score of 6.5/10. Comparable companies include AZN (QOC 10.0), CPRX (QOC 10.0), HRMY (QOC 10.0). The relative ranking helps investors identify whether VTVT offers better fundamental quality than alternatives in the same sector.
Is VTVT a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. VTVT's Quality Score of 6.5/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy VTVT at?
CirclFi does not provide target buy prices or price alerts. However, our 12 active models produce fair value estimates ranging from $29.50 to $78.73. At $31.67, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for VTVT.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad